245 related articles for article (PubMed ID: 22955994)
1. Protection from non-alcoholic steatohepatitis and liver tumourigenesis in high fat-fed insulin receptor substrate-1-knockout mice despite insulin resistance.
Nakamura A; Tajima K; Zolzaya K; Sato K; Inoue R; Yoneda M; Fujita K; Nozaki Y; Kubota KC; Haga H; Kubota N; Nagashima Y; Nakajima A; Maeda S; Kadowaki T; Terauchi Y
Diabetologia; 2012 Dec; 55(12):3382-91. PubMed ID: 22955994
[TBL] [Abstract][Full Text] [Related]
2. Lessons from mouse models of high-fat diet-induced NAFLD.
Nakamura A; Terauchi Y
Int J Mol Sci; 2013 Oct; 14(11):21240-57. PubMed ID: 24284392
[TBL] [Abstract][Full Text] [Related]
3. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
Morikawa R; Nakamoto N; Amiya T; Chu PS; Koda Y; Teratani T; Suzuki T; Kurebayashi Y; Ueno A; Taniki N; Miyamoto K; Yamaguchi A; Shiba S; Katayama T; Yoshida K; Takada Y; Ishihara R; Ebinuma H; Sakamoto M; Kanai T
J Hepatol; 2021 Mar; 74(3):511-521. PubMed ID: 33038434
[TBL] [Abstract][Full Text] [Related]
4. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis.
Asano T; Watanabe K; Kubota N; Gunji T; Omata M; Kadowaki T; Ohnishi S
J Gastroenterol Hepatol; 2009 Oct; 24(10):1669-76. PubMed ID: 19788607
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor alpha receptor 1 deficiency in hepatocytes does not protect from non-alcoholic steatohepatitis, but attenuates insulin resistance in mice.
Bluemel S; Wang Y; Lee S; Schnabl B
World J Gastroenterol; 2020 Sep; 26(33):4933-4944. PubMed ID: 32952340
[TBL] [Abstract][Full Text] [Related]
7. Bardoxolone methyl prevents insulin resistance and the development of hepatic steatosis in mice fed a high-fat diet.
Camer D; Yu Y; Szabo A; Dinh CH; Wang H; Cheng L; Huang XF
Mol Cell Endocrinol; 2015 Sep; 412():36-43. PubMed ID: 26001833
[TBL] [Abstract][Full Text] [Related]
8. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
9. The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model.
Yoshioka N; Tanaka M; Ochi K; Watanabe A; Ono K; Sawada M; Ogi T; Itoh M; Ito A; Shiraki Y; Enomoto A; Ishigami M; Fujishiro M; Ogawa Y; Suganami T
Biomed Pharmacother; 2021 Aug; 140():111738. PubMed ID: 34029949
[TBL] [Abstract][Full Text] [Related]
10. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition.
Charlton M; Krishnan A; Viker K; Sanderson S; Cazanave S; McConico A; Masuoko H; Gores G
Am J Physiol Gastrointest Liver Physiol; 2011 Nov; 301(5):G825-34. PubMed ID: 21836057
[TBL] [Abstract][Full Text] [Related]
11. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
[TBL] [Abstract][Full Text] [Related]
12. High-fat diet-induced nonalcoholic steatohepatitis is accelerated by low carnitine and impaired glucose tolerance in novel murine models.
Terayama Y; Nakamura SI; Mekada K; Matsuura T; Ozaki K
Lab Invest; 2022 Jun; 102(6):621-630. PubMed ID: 35039610
[TBL] [Abstract][Full Text] [Related]
13. Nrf2 deletion causes "benign" simple steatosis to develop into nonalcoholic steatohepatitis in mice fed a high-fat diet.
Wang C; Cui Y; Li C; Zhang Y; Xu S; Li X; Li H; Zhang X
Lipids Health Dis; 2013 Nov; 12():165. PubMed ID: 24188280
[TBL] [Abstract][Full Text] [Related]
14. Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis.
Lo L; McLennan SV; Williams PF; Bonner J; Chowdhury S; McCaughan GW; Gorrell MD; Yue DK; Twigg SM
J Hepatol; 2011 Aug; 55(2):435-44. PubMed ID: 21184785
[TBL] [Abstract][Full Text] [Related]
15. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer.
Wei G; An P; Vaid KA; Nasser I; Huang P; Tan L; Zhao S; Schuppan D; Popov YV
Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G174-G188. PubMed ID: 31630534
[TBL] [Abstract][Full Text] [Related]
16. Trans-Fatty Acids Aggravate Obesity, Insulin Resistance and Hepatic Steatosis in C57BL/6 Mice, Possibly by Suppressing the IRS1 Dependent Pathway.
Zhao X; Shen C; Zhu H; Wang C; Liu X; Sun X; Han S; Wang P; Dong Z; Ma X; Hu K; Sun A; Ge J
Molecules; 2016 May; 21(6):. PubMed ID: 27248994
[TBL] [Abstract][Full Text] [Related]
17. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
Sun G; Jackson CV; Zimmerman K; Zhang LK; Finnearty CM; Sandusky GE; Zhang G; Peterson RG; Wang YJ
BMC Gastroenterol; 2019 Mar; 19(1):41. PubMed ID: 30885145
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
[TBL] [Abstract][Full Text] [Related]
19. Myosteatosis rather than sarcopenia associates with non-alcoholic steatohepatitis in non-alcoholic fatty liver disease preclinical models.
Nachit M; De Rudder M; Thissen JP; Schakman O; Bouzin C; Horsmans Y; Vande Velde G; Leclercq IA
J Cachexia Sarcopenia Muscle; 2021 Feb; 12(1):144-158. PubMed ID: 33244884
[TBL] [Abstract][Full Text] [Related]
20. A novel and comprehensive mouse model of human non-alcoholic steatohepatitis with the full range of dysmetabolic and histological abnormalities induced by gold thioglucose and a high-fat diet.
Ogasawara M; Hirose A; Ono M; Aritake K; Nozaki Y; Takahashi M; Okamoto N; Sakamoto S; Iwasaki S; Asanuma T; Taniguchi T; Urade Y; Onishi S; Saibara T; Oben JA
Liver Int; 2011 Apr; 31(4):542-51. PubMed ID: 21382165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
